[Role of trimetazidine in the treatment of diabetic microangiopathy in ischaemic heart disease].
Diabetes is one of the largest public health problems nowadays. We have to consider appearance of micro- and macroangiopathic complications as early as the time of diagnosis. In diabetes mellitus type 2, one of the main complications is ischemic heart disease caused by atherosclerosis of the coronary arteries manifested clinically as angina pectoris and myocardial infarction. However, microangiopathy and secondary injury of myocardial tissue are also not uncommon complications. In the treatment of ischemic heart disease coronary interventions, medications dilating coronaries and decreasing blood pressure and heart rate are frequently applied. The authors draw attention to a drug having no hemodynamic effects, which improves the quality of life of patients via its effect on the metabolism of the myocardium.